Skip to main content
Hanx Biopharmaceuticals (Wuhan) Co., Ltd. logo

Hanx Biopharmaceuticals (Wuhan) Co., Ltd. — Investor Relations & Filings

Ticker · 3378 ISIN · CNE100007C34 HKEX Manufacturing
Open in API
Filings indexed 75 across all filing types
Latest filing 2026-05-29 Transaction in Own Shar…
Country HK Hong Kong
Listing HKEX 3378

About Hanx Biopharmaceuticals (Wuhan) Co., Ltd.

http://www.hanxbio.com

Hanx Biopharmaceuticals (Wuhan) Co., Ltd. is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative medicines, primarily focusing on immuno-oncology therapies for cancer and autoimmune diseases. The company leverages in-house capabilities in structural biology, translational medicine, and clinical development to build a high-value drug product pipeline. Key development activities include multiple clinical programs, such as trials for advanced melanoma and relapsed/refractory conditions. Its proprietary antibody technology platform drives the research and development of precise innovative therapeutics. Notable achievements include the marketing approval of the anti-PD-1 antibody Putilimab injection (developed in collaboration) and the FDA IND approval for its proprietary candidate, HX009.

Recent filings

Filing Released Lang Actions
Next Day Disclosure Return
Transaction in Own Shares Classification · 94% confidence The document is a Hong Kong Stock Exchange "Next Day Disclosure Return" (Form FF305) reporting a repurchase of its own shares, changes in issued and treasury shares, and compliance confirmations under Main Board and GEM Rules. It provides detailed share buyback/trading data (quantities, prices, dates) and confirms compliance with listing rules. This aligns with the "Transaction in Own Shares" category, which covers share repurchase/issuance disclosures under Listing Rules.
2026-05-29 English
Next Day Disclosure Return
Transaction in Own Shares Classification · 95% confidence The document is a Next Day Disclosure Return under Hong Kong Listing Rules detailing changes in issued shares and treasury shares, specifically the repurchase of shares on the Exchange. It provides a share repurchase report and related confirmations. This matches the “Transaction in Own Shares” category (Code: POS).
2026-05-28 English
Next Day Disclosure Return
Transaction in Own Shares Classification · 90% confidence The document is a Next Day Disclosure Return under Hong Kong Listing Rules, detailing changes in issued and treasury shares, including share repurchases and on-market sales of treasury shares. It provides specific trade dates, share counts, prices and confirmations of compliance with listing rules. This falls squarely under transactions in own shares (share buybacks) rather than a broader regulatory announcement or financial report. Therefore, it is classified as POS (Transaction in Own Shares).
2026-05-27 English
Next Day Disclosure Return
Transaction in Own Shares Classification · 95% confidence The document is a Hong Kong Stock Exchange “Next Day Disclosure Return” (FF305) under Main Board Rules/GEM Rules, detailing changes in issued shares, treasury shares, and a repurchase of shares. This is a mandated regulatory announcement of the company buying back its own shares. In our taxonomy, such share repurchase/sale disclosures fall under “Transaction in Own Shares” (POS).
2026-05-26 English
Next Day Disclosure Return
Transaction in Own Shares Classification · 92% confidence The document is a Hong Kong Stock Exchange FF305 Next Day Disclosure Return detailing changes in issued and treasury shares and a repurchase report (on-market share buybacks). It provides trading dates, number of shares repurchased, prices paid, opening/closing balances, and confirmations of compliance. This is a regulatory announcement of a share repurchase (transaction in own shares), which aligns directly with the Transaction in Own Shares category.
2026-05-22 English
Next Day Disclosure Return
Transaction in Own Shares Classification · 93% confidence The document is a Hong Kong Stock Exchange ‘Next Day Disclosure Return’ (Form FF305) detailing changes in issued shares, repurchase of own shares as treasury shares, and on-market sales of treasury shares under Main Board Rules/GEM Rules. It provides specific transaction details of share repurchases and confirmations thereof. This fits the category of a Transaction in Own Shares (share buybacks/issuance) rather than a general report or listing announcement. Therefore, the correct classification is POS.
2026-05-21 English

Browse filings by year

2 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.